Data mining in drug safety. Side effects of drugs essay

Side Effects of Drugs Annual

Volumn 29, Issue , 2007, Pages

  Hauben, Manfred ^a   Bate, Andrew ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34248669569     PISSN: 03786080     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0378-6080(06)29057-3     Document Type: Review

References (52)

1. Harris Jr. J.M. Coronary angiography and its complications. The search for risk factors. Arch Intern Med 144 (1984) 337-341
2. Bate A., Lindquist M., Edwards I.R., Olsson S., Orre R., Lansner A., and De Freitas R.M. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54 (1998) 315-321
3. Hauben M., and Reich L. Safety related drug-labelling changes: findings from two data mining algorithms. Drug Saf 27 (2004) 735-744
4. Evans S.J., Waller P.C., and Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10 (2001) 483-486
5. DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA Spontaneous Reporting System. Am Stat 53 (1999) 177-190
6. Bonacina S., Masseroli M., and Pinciroli F. Foreseeing promising bio-medical findings for effective applications of data mining. Biol Med Data Anal Proc (2005) 130-136
7. World Health Organization. The Importance of Pharmacovigilance. Geneva: WHO, 2002: 48
8. Waller P.C. Making the most of spontaneous adverse drug reaction reporting. Basic Clin Pharmacol Toxicol 98 (2006) 320-323
9. Frawley W., Piatetsky-Shapiro G., and Matheus C. Knowledge discovery in databases: an overview. AI Magazine (1992) 213-228
10. Gartner Group at url. http://gartner.com
11. Edwards I.R., and Biriell C. Harmonisation in pharmacovigilance. Drug Saf 10 (1994) 93-102
12. Edwards I.R. Pharmacological basis of adverse drug reactions. In: Speight T.M., and Holford H.G. (Eds). Avery's drug treatment. 4th ed (1997), Adis International, Auckland 261-299
13. Rawlins M.D. Spontaneous reporting of adverse drug reactions. II: Uses. Br J Clin Pharmacol 26 (1988) 7-11
14. Lexchin J. Is there still a role for spontaneous reporting of adverse drug reactions?. CMAJ 174 (2006) 191-192
15. Edwards I.R. Spontaneous reporting-of what? Clinical concerns about drugs. Br J Clin Pharmacol 48 (1999) 138-141
16. Trontell A. Expecting the unexpected-drug safety, pharmacovigilance, and the prepared mind. N Engl J Med 351 (2004) 1385-1387
17. Lokken P., and Skoglund L.A. Legemiddelbivirkninger i munnhulen. Adverse drug effects in the oral region. Tidsskr Nor Laegeforen 126 (2006) 1345-1348
18. Reddy J.C., Shuman M.A., and Aster R.H. Quinine/quinidine-induced thrombocytopenia: a great imitator. Arch Intern Med 164 (2004) 218-220
19. van Puijenbroek E.P., Bate A., Leufkens H.G., Lindquist M., Orre R., and Egberts A.C. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 11 (2002) 3-10
20. Finney D.J. Systemic signalling of adverse reactions to drugs. Methods Inf Med 13 (1974) 1-10
21. Stricker B.H., and Tijssen J.G. Serum sickness-like reactions to cefaclor. J Clin Epidemiol 45 (1992) 1177-1184
22. Meyboom R.H., Egberts A.C., Edwards I.R., Hekster Y.A., de Koning F.H., and Gribnau F.W. Principles of signal detection in pharmacovigilance. Drug Saf 16 (1997) 355-365
23. Hauben M., and Reich L. Communication of findings in pharmacovigilance: use of the term "signal" and the need for precision in its use. Eur J Clin Pharmacol 61 (2005) 479-480
24. Hauben M., Reich L., and Chung S. Postmarketing surveillance of potentially fatal reactions to oncology drugs: potential utility of two signal-detection algorithms. Eur J Clin Pharmacol 60 (2004) 747-750
25. Orre R., Lansner A., Bate A., and Lindquist M. Bayesian neural networks with confidence estimations applied to data mining. Comput Stat Data Anal 34 (2000) 473-493
26. Harter J.G. Acute flank pain and hematuria: lessons from adverse drug reaction reporting. J Clin Pharmacol 28 (1988) 560-565
27. Hauben M., and Reich L. Response to letter by Levine et al. Br J Clin Pharmacol 61 (2006) 115-117
28. Bate A., and Edwards I.R. Data mining in spontaneous reports. Basic Clin Pharmacol Toxicol 98 (2006) 324-330
29. Banta J.T., Hoffman K., Budenz D.L., Ceballos E., and Greenfield D.S. Presumed topiramate-induced bilateral acute angle-closure glaucoma. Am J Ophthalmol 132 (2001) 112-114
30. Almenoff J.S., LaCroix K.K., Yuen N.A., Fram D., and DuMouchel W. Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department. Drug Saf 29 (2006) 875-887
31. Hauben M., and Reich L. Potential utility of data-mining algorithms for early detection of potentially fatal/disabling adverse drug reactions: a retrospective evaluation. J Clin Pharmacol 45 (2005) 378-384
32. Hauben M, Reich L, Van Puijenbroek EP, Gerrits CM, Patadia VK. Data mining in pharmacovigilance: lessons from phantom ships, Eur J Clin Pharmacol 2006; August 3 [Epub ahead of print]
33. Diamond G.A., and Kaul S. Prior convictions: Bayesian approaches to the analysis and interpretation of clinical megatrials. J Am Coll Cardiol 43 (2004) 1929-1939
34. Gill C.J., Sabin L., and Schmid C.H. Why clinicians are natural Bayesians. BMJ 330 (2005) 1080-1083
35. Griffiths T., and Tenenbaum J. Statistics and the Bayesian mind. Significance 3 (2006) 130-133
36. Stahl M., Lindquist M., Edwards I.R., and Brown E.G. Introducing triage logic as a new strategy for the detection of signals in the WHO Drug Monitoring Database. Pharmacoepidemiol Drug Saf 13 (2004) 355-363
37. Edwards I.R., Lindquist M., Wiholm B.E., and Napke E. Quality criteria for early signals of possible adverse drug reactions. Lancet 336 (1990) 156-158
38. Meyboom R.H., Lindquist M., Egberts A.C., and Edwards I.R. Signal selection and follow-up in pharmacovigilance. Drug Saf 25 (2002) 459-465
39. Purcell P., and Barty S. Statistical techniques for signal generation: the Australian experience. Drug Saf 25 (2002) 415-421
40. Brown E.G. Methods and pitfalls in searching drug safety databases utilising the Medical Dictionary for Regulatory Activities (MedDRA). Drug Saf 26 (2003) 145-158
41. Brown E.G. Effects of coding dictionary on signal generation: a consideration of use of MedDRA compared with WHO-ART. Drug Saf 25 (2002) 445-452
42. Hauben M., Patadia V.K., and Goldsmith D. What counts in data mining?. Drug Saf 29 (2006) 827-832
43. Bousquet C., Henegar C., Louet A.L., Degoulet P., and Jaulent M.C. Implementation of automated signal generation in pharmacovigilance using a knowledge-based approach. Int J Med Inform 74 (2005) 563-571
44. Aronson J.K., and Ferner R.E. Joining the DoTS: new approach to classifying adverse drug reactions. BMJ 327 (2003) 1222-1225
45. Orre R., Bate A., Norén G.N., Swahn E., Arnborg S., and Edwards I.R. A Bayesian recurrent neural network approach for finding dependencies in large incomplete data sets. Int J Neural Syst 15 (2005) 207-222
46. DuMouchel W., and Pregibon D. Empirical Bayes screening for multi-item associations. Proceedings of the Seventh ACM SIGKDD International conference on Knowledge Discovery and Data Mining 00 (2001) 67-76
47. Noren GN, Orre R, Bate A. Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events. Stat Med 2006; in press
48. van Puijenbroek E.P., Egberts A.C., Heerdink E.R., and Leufkens H.G. Detecting drug-drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol 56 (2000) 733-738
49. Strandell J., Kiuru A., and Lindquist M. Linking spontaneous reports with pharmacogenetics. Basic Clin Pharmacol Toxicol 97 (2005) 106
50. Noren GN, Orre R, Bate A. A hit-miss model for duplicate detection in the WHO Drug Safety Database. In: Proceedings of the Eleventh ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, 2005
51. Bate A., Edwards I.R., Edwards J., Swahn E., Noren G.N., and Lindquist M. Knowledge finding in IMS disease analyser Mediplus UK database-effective data mining in longitudinal patient safety data. Drug Saf 27 (2004) 917-918
52. Mitka M. Report criticizes lack of FDA oversight. JAMA 296 (2006) 920-922